retatrutide triple hormone receptor agonist benefits Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Let's talk retatrutide — the

Clinical Reviewer Pharmacy prescriber Craig is based in the UK and regularly reviews our content to ensure clinical accuracy

All scientific concepts, interpretations, and conclusions were conceived, verified, and critically reviewed by the authors, who take full responsibility for the content

Mozaffarian, a cardiologist and epidemiologist, studies the health effects of dietary habits and other lifestyle factors in large populations

This is particularly relevant for fertility-focused use, where treatment duration is time-bounded, washout is mandatory, and downstream reproductive outcomes remain uncertain

The study met its primary endpoint of reduced side effects vs the Rybelsus control arm